{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Adynovate&page=2",
    "query": {
      "intervention": "Adynovate",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Adynovate&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-26T00:44:46.407Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03876301",
      "title": "Lead-in Study to Collect Prospective Efficacy and Safety Data of Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Participants",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Blood Coagulation Disorder",
        "Blood Coagulation Disorders, Inherited",
        "Coagulation Protein Disorders",
        "Hemophilia A",
        "Genetic Diseases, Inborn",
        "Genetic Diseases, X-Linked",
        "Hematologic Diseases",
        "Hemorrhagic Disorders",
        "Factor VIII Deficiency"
      ],
      "interventions": [
        {
          "name": "Standard of Care FVIII Replacement therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Spark Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 25,
      "start_date": "2019-01-21",
      "completion_date": "2023-05-02",
      "has_results": false,
      "last_update_posted_date": "2023-07-10",
      "last_synced_at": "2026-09-26T00:44:46.407Z",
      "location_count": 6,
      "location_summary": "San Francisco, California • Gainesville, Florida • Atlanta, Georgia + 3 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Madison",
          "state": "Mississippi"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03876301"
    },
    {
      "nct_id": "NCT05932914",
      "title": "Liver Biopsy Following Gene Therapy For Hemophilia",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hemophilia A",
        "Hemophilia B"
      ],
      "interventions": [
        {
          "name": "Liver Biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "MALE",
        "summary": "18 Years to 80 Years · Male only"
      },
      "enrollment_count": 8,
      "start_date": "2026-10",
      "completion_date": "2030-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-17",
      "last_synced_at": "2026-09-26T00:44:46.407Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05932914"
    },
    {
      "nct_id": "NCT04621916",
      "title": "Preventing Inhibitor Recurrence Indefinitely",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hemophilia A",
        "Immune Tolerance"
      ],
      "interventions": [
        {
          "name": "FVIII",
          "type": "DRUG"
        },
        {
          "name": "Emicizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's Hospital Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "12 Years",
        "sex": "MALE",
        "summary": "0 Years to 12 Years · Male only"
      },
      "enrollment_count": 52,
      "start_date": "2020-09-21",
      "completion_date": "2025-04-20",
      "has_results": false,
      "last_update_posted_date": "2023-10-05",
      "last_synced_at": "2026-09-26T00:44:46.407Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04621916"
    },
    {
      "nct_id": "NCT02830477",
      "title": "Study Evaluating \"Real World\" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hemophilia A, Congenital"
      ],
      "interventions": [
        {
          "name": "Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 313,
      "start_date": "2016-10-14",
      "completion_date": "2021-03-01",
      "has_results": false,
      "last_update_posted_date": "2023-11-07",
      "last_synced_at": "2026-09-26T00:44:46.407Z",
      "location_count": 13,
      "location_summary": "Mobile, Alabama • Aurora, Colorado • Gainesville, Florida + 10 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Pensacola",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02830477"
    },
    {
      "nct_id": "NCT02577614",
      "title": "FEIBA and Use of Blood Products in Cardiac Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cardiovascular Disease"
      ],
      "interventions": [
        {
          "name": "FEIBA",
          "type": "DRUG"
        },
        {
          "name": "Normal Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oregon Health and Science University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 12,
      "start_date": "2016-02",
      "completion_date": "2020-03",
      "has_results": false,
      "last_update_posted_date": "2020-07-14",
      "last_synced_at": "2026-09-26T00:44:46.407Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02577614"
    },
    {
      "nct_id": "NCT05935358",
      "title": "Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Severe Hemophilia A"
      ],
      "interventions": [
        {
          "name": "Nuwiq",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Octapharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "12 Years and older · Male only"
      },
      "enrollment_count": 28,
      "start_date": "2023-11-28",
      "completion_date": "2026-09",
      "has_results": false,
      "last_update_posted_date": "2026-05-12",
      "last_synced_at": "2026-09-26T00:44:46.407Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05935358"
    },
    {
      "nct_id": "NCT06349473",
      "title": "A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants",
        "Hemophilia A",
        "Hemophilia B",
        "Factor VII Deficiency"
      ],
      "interventions": [
        {
          "name": "SR604",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Equilibra Bioscience LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 31,
      "start_date": "2024-05-10",
      "completion_date": "2026-09-28",
      "has_results": false,
      "last_update_posted_date": "2026-07-02",
      "last_synced_at": "2026-09-26T00:44:46.407Z",
      "location_count": 9,
      "location_summary": "Glendale, California • Los Angeles, California • Chicago, Illinois + 6 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Metairie",
          "state": "Louisiana"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06349473"
    },
    {
      "nct_id": "NCT07032792",
      "title": "Factor VIII Inhibitor Bypass Activity (FEIBA) Versus Fresh Frozen Plasma As First Line Therapy For Bleeding After Cardiac Surgery",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cardiac Disease",
        "Surgery",
        "Bleeding"
      ],
      "interventions": [
        {
          "name": "FEIBA",
          "type": "DRUG"
        },
        {
          "name": "FFP",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwell Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 140,
      "start_date": "2025-11-03",
      "completion_date": "2029-11",
      "has_results": false,
      "last_update_posted_date": "2026-03-11",
      "last_synced_at": "2026-09-26T00:44:46.407Z",
      "location_count": 1,
      "location_summary": "Manhasset, New York",
      "locations": [
        {
          "city": "Manhasset",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07032792"
    },
    {
      "nct_id": "NCT03248141",
      "title": "Understanding Hemophilia A and B Drug Dosage Administration Patterns",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hemophilia A",
        "Hemophilia B"
      ],
      "interventions": [
        {
          "name": "Hemophilia B standard half-life",
          "type": "DRUG"
        },
        {
          "name": "Hemophilia B extended half-life",
          "type": "DRUG"
        },
        {
          "name": "Hemophilia A standard half-life",
          "type": "DRUG"
        },
        {
          "name": "Hemophilia A extended half-life",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 11,
      "start_date": "2017-09-01",
      "completion_date": "2018-03-14",
      "has_results": true,
      "last_update_posted_date": "2019-05-20",
      "last_synced_at": "2026-09-26T00:44:46.407Z",
      "location_count": 3,
      "location_summary": "Gainesville, Florida • Las Vegas, Nevada • Fort Worth, Texas",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03248141"
    },
    {
      "nct_id": "NCT02083965",
      "title": "Pharmacokinetics of rFVIIIFc at Two Vial Strengths",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Severe Hemophilia A"
      ],
      "interventions": [
        {
          "name": "rFVIIIFc",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bioverativ Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "12 Years and older · Male only"
      },
      "enrollment_count": 19,
      "start_date": "2014-03",
      "completion_date": "2015-05",
      "has_results": true,
      "last_update_posted_date": "2020-12-19",
      "last_synced_at": "2026-09-26T00:44:46.407Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Salt Lake City, Utah • Seattle, Washington",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02083965"
    }
  ]
}